InvestorsHub Logo
Post# of 252311
Next 10
Followers 50
Posts 6343
Boards Moderated 0
Alias Born 01/22/2006

Re: DewDiligence post# 219874

Thursday, 06/28/2018 6:51:55 PM

Thursday, June 28, 2018 6:51:55 PM

Post# of 252311
GLPG / ABBV:

The company (GLPG) had been guiding to about 5 as a good sign of efficacy. I think analysts were putting the low at 8%. I certainly am disappointed with the results (and would have with anything in the 5% range too).

I have been suggesting for some time that the two companies are not seeing eye-to-eye on the development path. Clearly, GLPG is much more aggressive (I think they have more cash then know what to do with so prefer to push everything forward and see where the data leads).

While a setback they have a pretty big development program in CF. They said about trying to dose 2737 higher and have another C2 corrector (3221) a bit further behind so I highly doubt they want to stop pursuing CF.

I am guessing they did/will claim ABBV is in material breach by not pursuing the second triple. Its a bit hard to gain useful information from the amended agreement (perhaps someone more skilled then I can!).

Here is the link termination starts on page 102:
https://www.sec.gov/Archives/edgar/data/1421876/000119312516610049/d201818dex101.htm

Here is my tweet saying pretty much the same thing smile
https://twitter.com/MauriceOnTW/status/1012465709119623168

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.